---
title: "COMPASS Pathways (NASDAQ:CMPS) Releases  Earnings Results, Misses Estimates By $0.01 EPS"
description: "COMPASS Pathways (NASDAQ:CMPS) reported quarterly earnings of ($0.38) per share, missing estimates by $0.01. The stock traded down 0.2% to $4.34, with a market cap of $406.05 million. Analysts have mi"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/251344462.md"
published_at: "2025-08-03T15:55:20.000Z"
---

# COMPASS Pathways (NASDAQ:CMPS) Releases  Earnings Results, Misses Estimates By $0.01 EPS

> COMPASS Pathways (NASDAQ:CMPS) reported quarterly earnings of ($0.38) per share, missing estimates by $0.01. The stock traded down 0.2% to $4.34, with a market cap of $406.05 million. Analysts have mixed ratings, with a consensus target price of $17.00. Institutional investors own 46.19% of the company, which focuses on psilocybin therapy for mental health conditions. Despite a Moderate Buy rating, COMPASS Pathways is not among the top stocks recommended by analysts.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.38) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.01), Zacks reports.

Get **COMPASS Pathways** alerts:

## COMPASS Pathways Trading Down 0.2%

Shares of NASDAQ:CMPS traded down $0.01 during midday trading on Friday, hitting $4.34. 2,524,177 shares of the stock were exchanged, compared to its average volume of 2,277,808. The stock has a market capitalization of $406.05 million, a price-to-earnings ratio of -2.36 and a beta of 2.16. The company has a debt-to-equity ratio of 0.11, a quick ratio of 10.18 and a current ratio of 10.18. The business's 50-day moving average price is $3.99 and its 200 day moving average price is $3.80. COMPASS Pathways has a 12 month low of $2.25 and a 12 month high of $8.54.

## Analysts Set New Price Targets

CMPS has been the topic of several research analyst reports. Evercore ISI reaffirmed an "in-line" rating and issued a $6.00 price objective (down from $11.00) on shares of COMPASS Pathways in a research note on Monday, June 23rd. HC Wainwright reiterated a "buy" rating and issued a $45.00 target price on shares of COMPASS Pathways in a research report on Tuesday, July 15th. Canaccord Genuity Group reiterated a "buy" rating and issued a $15.00 target price on shares of COMPASS Pathways in a research report on Friday. Finally, Cantor Fitzgerald reiterated an "overweight" rating and issued a $12.00 target price on shares of COMPASS Pathways in a research report on Tuesday, May 27th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $17.00.

**Read Our Latest Research Report on CMPS**

## Institutional Trading of COMPASS Pathways

An institutional investor recently raised its position in COMPASS Pathways stock. Royal Bank of Canada lifted its position in shares of COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS - Free Report) by 49.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 89,446 shares of the company's stock after purchasing an additional 29,733 shares during the period. Royal Bank of Canada owned about 0.10% of COMPASS Pathways worth $256,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 46.19% of the company's stock.

## COMPASS Pathways Company Profile

(Get Free Report)

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.

## See Also

-   Five stocks we like better than COMPASS Pathways
-   How to Invest in Tech Stocks and Top Tech Stocks to Consider
-   Bitcoin and Dividends: A Winning Combo in These 3 ETFs
-   The How And Why of Investing in Oil Stocks
-   Is PG&E an AI Power Play? Why Options Traders Are Betting Big
-   How to Evaluate a Stock Before Buying
-   MarketBeat Week in Review – 07/28 - 08/01

*This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.*

## Should You Invest $1,000 in COMPASS Pathways Right Now?

Before you consider COMPASS Pathways, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and COMPASS Pathways wasn't on the list.

While COMPASS Pathways currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

### Related Stocks

- [CMPS.US - Compass Pathways](https://longbridge.com/en/quote/CMPS.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| COMPASS Pathways (CMPS) Gets a Buy from H.C. Wainwright | H.C. Wainwright analyst Patrick Trucchio has reiterated a Buy rating on COMPASS Pathways (CMPS) with a price target of $ | [Link](https://longbridge.com/en/news/274015740.md) |
| Compass Pathways unveils investor presentation highlighting COMP360 Phase 3 results in treatment-resistant depression | Compass Pathways plc has released an investor presentation detailing its clinical development progress in mental health, | [Link](https://longbridge.com/en/news/271781512.md) |
| Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD \| CMPS Stock News | Compass Pathways announced that the FDA has accepted its IND application for COMP360, allowing the start of a late-stage | [Link](https://longbridge.com/en/news/271781731.md) |
| COMPASS Pathways Unveils Pivotal PTSD Trial Design, Teases Key Phase 3 TRD Data in Q1 Webinar | COMPASS Pathways (NASDAQ:CMPS) has announced updates on its COMP360 psilocybin programs for PTSD and treatment-resistant | [Link](https://longbridge.com/en/news/271825606.md) |
| Compass Pathways Expands Loan Facility With Hercules Capital to $150 Million | Compass Pathways plc has expanded its loan facility with Hercules Capital, increasing the total financing to $150 millio | [Link](https://longbridge.com/en/news/271780898.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
